Question 1

What is Regeneron Pharmaceuticals's P/B ratio?

Accepted Answer

Regeneron Pharmaceuticals (REGN) P/B ratio is 2.2× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for Regeneron Pharmaceuticals?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For Regeneron Pharmaceuticals specifically, the relevant sector benchmark is the current sector median of 3.2×.

Question 5

Is Regeneron Pharmaceuticals's P/B ratio high or low?

Accepted Answer

Regeneron Pharmaceuticals's P/B ratio of 2.2× is below its own 5-year average of 3.3× and below the sector median of 3.2×. That places the current reading at the 13th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Regeneron Pharmaceuticals's historical P/B ratio range?

Accepted Answer

In the available daily series, Regeneron Pharmaceuticals (REGN) P/B ratio has ranged from a low of 1.5× in 2005 to a high of 21.6× in 2012. The 5-year average is 3.3× and the 5-year median is 3.5×.

Question 7

What was Regeneron Pharmaceuticals's P/B ratio in 2025?

Accepted Answer

Regeneron Pharmaceuticals (REGN) P/B ratio at the end of 2025 was 2.5×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does Regeneron Pharmaceuticals's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$79.4B	$31.3B	2.5×	-0.1×	Dec 31, 2025
2024	$76.9B	$29.4B	2.6×	-1.0×	Dec 31, 2024
2023	$93.6B	$26B	3.6×	+0.2×	Dec 31, 2023
2022	$77.2B	$22.7B	3.4×	-0.2×	Dec 31, 2022
2021	$67.1B	$18.8B	3.6×	-1.0×	Dec 31, 2021
2020	$50.9B	$11B	4.6×	+0.7×	Dec 31, 2020
2019	$42.9B	$11.1B	3.9×	-1.0×	Dec 31, 2019
2018	$42.9B	$8.76B	4.9×	-2.2×	Dec 31, 2018
2017	$43.6B	$6.14B	7.1×	-2.5×	Dec 31, 2017
2016	$42.5B	$4.45B	9.6×	-7.6×	Dec 31, 2016
2015	$62.7B	$3.65B	17.2×	-1.3×	Dec 31, 2015
2014	$46.9B	$2.54B	18.4×	-0.2×	Dec 31, 2014
2013	$36.3B	$1.95B	18.6×	+3.4×	Dec 31, 2013
2012	$18.9B	$1.25B	15.2×	+4.7×	Dec 31, 2012
2011	$5.09B	$486M	10.5×	+5.0×	Dec 31, 2011
2010	$2.87B	$528M	5.4×	+0.6×	Dec 31, 2010
2009	$1.94B	$397M	4.9×	+1.4×	Dec 31, 2009
2008	$1.45B	$419M	3.5×	-0.6×	Dec 31, 2008
2007	$1.9B	$460M	4.1×	-2.0×	Dec 31, 2007
2006	$1.32B	$217M	6.1×	-1.7×	Dec 31, 2006
2005	$892M	$114M	7.8×	+5.0×	Dec 31, 2005
2004	$512M	$183M	2.8×	-3.1×	Dec 31, 2004
2003	$809M	$138M	5.9×	+0.3×	Dec 31, 2003
2002	$817M	$146M	5.6×	—	Dec 31, 2002


Moderna (MRNA)	2.7×
Charles River (CRL)	2.6×
Danaher (DHR)	2.6×
Spruce Biosciences (SPRB)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Solventum (SOLV)	2.3×
Medtronic (MDT)	2.2×
Elevance Health (ELV)	1.9×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Zimmer Biomet Holdings (ZBH)	1.4×
Revvity (RVTY)	1.4×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Ovid Therapeutics (OVID)	0.8×
Centene (CNC)	0.8×
Teladoc Health (TDOC)	0.7×

P/B Ratio for Regeneron Pharmaceuticals (REGN) 2002-2026

P/B Ratio daily chart for Regeneron Pharmaceuticals (REGN)

Historical P/B Ratio for Regeneron Pharmaceuticals (REGN) from 2002 to 2025

About P/B Ratio at Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals P/B Ratio by Year

Regeneron Pharmaceuticals P/B Ratio 2025: 2.5×

Regeneron Pharmaceuticals P/B Ratio 2024: 2.6×

Regeneron Pharmaceuticals P/B Ratio 2023: 3.6×

Regeneron Pharmaceuticals P/B Ratio 2022: 3.4×

Regeneron Pharmaceuticals P/B Ratio 2021: 3.6×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Key Financials